Does your institution provide guidelines as to when a patient with COVID-19 needs intensive care? Do these parameters change based on hospital capacity?
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on March 10, 2021
Which markers or patient features would cause you to choose noninvasive or high-flow nasal cannula over intubation for early management of COVID-19 respiratory failure?
For patients with COVID-19 being treated with intermediate- or full-dose enoxaparin, have anti-Xa levels been checked? If so, have higher-than-expected anti-Xa levels been found?
Should anticoagulation or antiplatelet therapy be used for patients with COVID-19? Should these patients be empirically anticoagulated? How is your institution handling this?
At your institution, have you used procalcitonin as a trending marker to aid in the identification of pulmonary infection?
For patients who have acute respiratory distress syndrome from COVID-19 and are on a ventilator, how do you identify secondary lung infections?
Do you favor pressure or volume control ventilation in patients with acute respiratory distress syndrome from COVID-19?
Does ketamine help resolve agitation or delirium? Are hallucinations a possible side effect of ketamine?
For patients with severe acute respiratory distress syndrome from COVID-19, how do you prevent delirium when you cannot provide a sedation vacation or spontaneous breathing trial?
When delirium prevention measures are ineffective for ICU patients with delirium, which therapies do you recommend trying next?
The Society of Critical Care Medicine’s (SCCM) COVID-19 Rapid Resource Center gives you access to the latest education.
Looking for more: